1.8K views · 67 reactions | Adagrasib is an inhibitor of mutant KRAS G12C. The efficacy of adagrasib in the treatment of KRAS G12C–mutated colorectal cancer, used either alone or with cetuximab, has been uncertain. New research findings are summarized in a short video. https://nej.md/3vANNHq | The New England Journal of Medicine | Facebook

2.5K views · 73 reactions | Sotorasib is approved in the United States to treat KRAS p.G12C–mutated non–small-cell lung cancer. Its efficacy and safety in KRAS p.G12C–mutated pancreatic cancer have been unknown. New research findings are summarized in a short video. https://nej.md/3GfOXNp | The New England Journal of Medicine | Facebook